Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.
BACKGROUND
In order to induce a potent and cross-reactive neutralizing antibody (nAb), an effective envelope immunogen is crucial for many viral vaccines, including the vaccine for the human immunodeficiency virus (HIV). The Chinese equine infectious anemia virus (EIAV) attenuated vaccine has controlled the epidemic of this virus after its vaccination in over 70 million equine animals during the last 3 decades in China. Data from our past studies demonstrate that the Env protein of this vaccine plays a pivotal role in protecting horses from both homologous and heterogeneous EIAV challenges. Therefore, the amino acid sequence information from the Chinese EIAV attenuated vaccine, in comparison with the parental wild-type EIAV strains, was applied to modify the corresponding region of the envelope glycoprotein of HIV-1 CN54. The direction of the mutations was made towards the amino acids conserved in the two EIAV vaccine strains, distinguishing them from the two wild-type strains. The purpose of the modification was to enhance the immunogenicity of the HIV Env.


RESULTS
The induced nAb by the modified HIV Env neutralized HIV-1 B and B'/C viruses at the highest titer of 1:270. Further studies showed that a single amino acid change in the C1 region accounts for the substantial enhancement in induction of anti-HIV-1 neutralizing antibodies.


CONCLUSIONS
This study shows that an HIV envelope modified by the information of another lentivirus vaccine induces effective broadly neutralizing antibodies. A single amino acid mutation was found to increase the immunogenicity of the HIV Env.
Liu
Lianxing
L
State Key Laboratory for Infectious Diseases Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 155 Changbai Road, Changping District, Beijing 102206, China.
Wan
Yanmin
Y
Wu
Lan
L
Sun
Jianping
J
Li
Huiguang
H
Li
Haishan
H
Ma
Liying
L
Shao
Yiming
Y
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D019943:Amino Acid Substitution; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D002681:China; D003429:Cross Reactions; D018604:Epitope Mapping; D005260:Female; D005822:Genetic Vectors; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000097:blood*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D004860:Infectious Anemia Virus, Equine / Q000235:genetics*; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D019444:Vaccines, DNA; D054299:env Gene Products, Human Immunodeficiency Virus; D007371:Interferon-gamma
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8
11997472
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15105-10
17846425
Virus Res. 1994 May;32(2):111-38
8067050
AIDS Res Hum Retroviruses. 2005 Dec;21(12):1057-9
16379610
J Virol. 2005 Dec;79(23):14489-97
16282448
Arch Virol. 2006 Jul;151(7):1387-403
16502285
J Virol. 1997 Dec;71(12):9808-12
9371651
AIDS Res Hum Retroviruses. 2003 Oct;19(10):923-4
14601590
AIDS Res Hum Retroviruses. 2007 Nov;23(11):1396-404
18184083
J Virol. 2002 Mar;76(5):2075-86
11836385
Rev Infect Dis. 1985 Jan-Feb;7(1):83-8
2984759
J Virol. 2003 Jul;77(13):7244-53
12805423
AIDS. 2000;14 Suppl 3:S141-51
11086857
Vet Res. 2004 Jul-Aug;35(4):485-512
15236678
Retrovirology. 2009 May 14;6:45
19442296
J Virol. 2002 May;76(9):4222-32
11932387
Virology. 2007 Jun 20;363(1):79-90
17306322
Dev Biol Stand. 1990;72:31-7
2178127
J Immunol. 2003 Aug 15;171(4):1984-93
12902502
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S255-9
9814952
Expert Rev Vaccines. 2006 Jun;5(3):347-63
16827619
J Virol. 1998 Oct;72(10):7852-9
9733822
J Virol. 2001 Feb;75(4):2014-8
11160703
Curr Pharm Des. 2007;13(2):213-27
17269929
J Virol. 2000 Aug;74(16):7187-95
10906172
Clin Microbiol Rev. 1996 Jan;9(1):100-17
8665473
J Virol. 2004 Mar;78(5):2478-85
14963146
J Virol. 1999 Jun;73(6):4952-61
10233957
J Virol. 2007 Jun;81(12):6402-11
17392364
Proc Natl Acad Sci U S A. 1986 Jun;83(11):4007-11
2424014
AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1129-39
9737584
J Virol. 1999 Oct;73(10):8356-63
10482586
Science. 1999 Jan 15;283(5400):357-62
9888845
J Virol. 2008 Apr;82(8):4052-63
18234792
Annu Rev Genet. 1999;33:133-70
10690406
J Virol. 1997 May;71(5):3840-52
9094660
J Virol. 2005 Mar;79(6):3358-69
15731230
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8
17540729
J Virol. 2005 Apr;79(8):4828-37
15795268
Vaccine. 2007 Jan 15;25(5):834-45
17023099
Virology. 1987 Dec;161(2):321-31
2825406
J Virol. 1997 Jul;71(7):5069-79
9188572
Curr HIV Res. 2007 Nov;5(6):514-41
18045109
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7
12192089
J Virol. 2002 Jun;76(12):6138-46
12021347
J Virol. 1995 May;69(5):2737-44
7707496
J Med Primatol. 2000 Aug;29(3-4):220-30
11085584
Virology. 1999 Sep 30;262(2):416-30
10502520